search
Back to results

Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs (POSITIVE)

Primary Purpose

Frailty, Frailty Syndrome, Frail Elderly Syndrome

Status
Unknown status
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Frailty multicomponent intervention supported by POSITIVE
Frailty multicomponent intervention
Sponsored by
Hospital Universitario Getafe
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Frailty focused on measuring Frailty, Technology, Home monitoring, Older persons

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Age ≥ 70.
  • Living at home.
  • Having a caregiver/relative and/or supervision at home.
  • Barthel ≥ 90.
  • Meet at least 1 criterion from Fried's Criteria.

Exclusion criteria:

  • Inadequate home infrastructure to host the required technology.
  • Inability to understand on how to use the POSITIVE system by the participant.
  • Diseases that may affect prescription therapy:
  • History of alcohol/drugs abuse.
  • Living with another participant.
  • Participating in other clinical studies.
  • Three or more hospitalizations in the last year.

Sites / Locations

  • Medical University of Lodz
  • Fundación para la Investigación Biomédica - Hospital Universitario de GetafeRecruiting
  • Karolinska Institutet

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Control group

Intervention group

Arm Description

Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.

Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person. As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected.

Outcomes

Primary Outcome Measures

Frailty status 1
Evaluation of the impact of the technology supported intervention in terms of frailty measured with the Linda Fried's criteria. This test ranges from 0 to 5 (0: robust; 1-2: pre-frailty; +2: frailty).
Frailty status 2
To evaluate whether a multimodal intervention supported by the POSITIVE technological ecosystem improves frailty in at least 5 points in Frail trait scale (FTS-5) during a 6-month follow-up period. FTS scores between 0-50. 0 is the best value and 50 the worst value.

Secondary Outcome Measures

Frailty trajectories 1
Trajectories of frailty according to changes in Fried´s phenotype. Fried´s Phenotype scores between 0 and 5. 0 means robust; 1-2 mean pre-frail and 3 or more mean frail
Frailty trajectories 2
To evaluate whether the POSITIVE system improves frailty transitions in pre-frail and frail participants according to FTS-5.
Physical function 1
To evaluate whether the POSITIVE system improves participants' physical performance according to the Short Physical Performance Battery (SPPB).SPPB scores between 0-12. 0 is the worst and 12 the best value.
Physical function 2
To evaluate whether the POSITIVE system improves participants' physical performance according to the Gait Speed test (meters/second)
Basic activities daily living (BADL)
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (basic activities) according to the Barthel Index. Barthel scores between 0-100; 0 is the worst value and 100 the best.
Disability
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to WHO Disability Assessment Schedule (WHODAS 2.0). Score between 0 to 100 (where 0 = no disability; 100 = full disability)
Instrumental activities of daily living (IADL)
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to the Lawton and Brody scale. Lawton and Brody scale scores between 0-10; 0 is the worst and 10 the best value.
Health-related quality of life
To evaluate the influence of the POSITIVE system in the quality of life according to the European Quality of life 5 dimensions-5 levels (EuroQoL 5D-5L). EuroQoL scores between 0-10 and 10 is the worst quality of life.
Cognitive impairment 1
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the MONTREAL COGNITIVE ASSESSMENT (MoCA test). Scores between 0-30 being 30 the best value.
Cognitive impairment 2
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the clock drawing test. Score ranges between 0-10. <8 suggests that cognitive impairment (CI)
Affective sphere
To evaluate the influence of the POSITIVE system in the affective sphere according Geriatric Depression Scale (GDS). Each answer indicating depression (bold 'yes' or 'no) counts one point. Scores greater than 5 are indicative of probable depression. In the experimental site located in Sweden, the version of this scale will be used.
Caregiver quality of life
To evaluate the influence of the POSITIVE system on the caregiver quality of life according EuroQoL-5D-5L.
To evaluate the usability of the POSITIVE system according to the System Usability Scale (SUS).
SUS ranges from 0 to 100. A SUS score above a 68 would be considered above average and anything below 68 is below average..

Full Information

First Posted
September 30, 2020
Last Updated
February 9, 2021
Sponsor
Hospital Universitario Getafe
Collaborators
Karolinska Institutet, Medical University of Lodz, Universidad Politecnica de Madrid, KTH Royal Institute of Technology, Fundación para la Investigación Biomédica - Hospital Universitario de Getafe
search

1. Study Identification

Unique Protocol Identification Number
NCT04592146
Brief Title
Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs
Acronym
POSITIVE
Official Title
POSITIVE: Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
November 1, 2020 (Actual)
Primary Completion Date
June 30, 2021 (Anticipated)
Study Completion Date
June 30, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospital Universitario Getafe
Collaborators
Karolinska Institutet, Medical University of Lodz, Universidad Politecnica de Madrid, KTH Royal Institute of Technology, Fundación para la Investigación Biomédica - Hospital Universitario de Getafe

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The POSITIVE platform offers the possibility of unsupervised monitoring of pre-frailty and frailty status in a community setting, to detect the onset of frailty and to assess its evolution. The primary objective of the study is to evaluate whether the POSITIVE system improves frailty in at least 1 point in the Fried's Criteria and 5 points in the FTS-5. This is a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with a 12-month follow up duration. The study will be carried out in Spain, Sweden and Poland. 150 participants will be randomized into two groups. The control group will receive usual medical care. The intervention group will receive, in addition, the POSITIVE frailty home monitoring and intervention system.
Detailed Description
The primary endpoints is to evaluate whether a multimodal intervention supported by the POSITIVE technological ecosystem improves frailty in at least 1 point in Fried's Criteria and 5 points in FTS-5 during a 6-month follow-up period. This objective will be investigated through a multi-centre, non-inferiority, randomized, simple blind and prospective pilot study with an intervention lasting for 6 months. The study will be carried out in Spain, Sweden and Poland. 150 participants (50 per site) will be randomized into two groups. The control group will receive usual medical care. The intervention group will receive, in addition, the POSITIVE frailty home monitoring and intervention system. Both groups will be assessed with the same instruments. This assessment will be conducted at baseline (in the beginning of the trial period), at the middle (month 3) and at the end of the intervention (month 6). A stratified randomization technique will be applied in each of the study groups based on: age group (70-85,> 85), history of cognitive impairment, history of stroke to guarantee the existence of comparable groups. These factors have been significantly associated with frailty and pre-frailty status (stroke OR =3.11 (1.05-9.18), age, per 1-year OR = 1.14 (1.08-1.21); cognitive impairment OR = 8.37 (4.43-15.83)).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Frailty, Frailty Syndrome, Frail Elderly Syndrome
Keywords
Frailty, Technology, Home monitoring, Older persons

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Multi-centre, non-inferiority, randomized, simple blind and prospective pilot study.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control group
Arm Type
Active Comparator
Arm Description
Participants randomized into the intervention group will receive care according to the current organizational model in each pilot site (managed by community care). Frailty care will consist in a multicomponent intervention.
Arm Title
Intervention group
Arm Type
Experimental
Arm Description
Participants randomized into the intervention group will receive the same intervention as those allocated into the control group, but this intervention will be supported by the POSITIVE technology.Informal caregivers will also receive an app to follow the evolution of the cared person. As in the control group, participants allocated into the intervention group will be managed by community care; these professionals will have access to the evolution of the older persons so they can take promote actions in case early deterioration is detected.
Intervention Type
Device
Intervention Name(s)
Frailty multicomponent intervention supported by POSITIVE
Intervention Description
This technology mainly consists in a home monitoring kit periodically measuring gait speed, involuntary weight loss and power in the lower limb. Furthermore, through a tablet device, other relevant information (e.g. state of mind, activities of daily living-ADLs, etc.) is collected. The same device is used to enhance communication with the clinical team and follow the tailored intervention
Intervention Type
Other
Intervention Name(s)
Frailty multicomponent intervention
Intervention Description
This intervention is based on 3 main pillars: medication review (to avoid polypharmacy), tailored nutritional recommendations and a tailored physical activity plan based on the VIVIFRAIL program.
Primary Outcome Measure Information:
Title
Frailty status 1
Description
Evaluation of the impact of the technology supported intervention in terms of frailty measured with the Linda Fried's criteria. This test ranges from 0 to 5 (0: robust; 1-2: pre-frailty; +2: frailty).
Time Frame
6 months
Title
Frailty status 2
Description
To evaluate whether a multimodal intervention supported by the POSITIVE technological ecosystem improves frailty in at least 5 points in Frail trait scale (FTS-5) during a 6-month follow-up period. FTS scores between 0-50. 0 is the best value and 50 the worst value.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Frailty trajectories 1
Description
Trajectories of frailty according to changes in Fried´s phenotype. Fried´s Phenotype scores between 0 and 5. 0 means robust; 1-2 mean pre-frail and 3 or more mean frail
Time Frame
6 months
Title
Frailty trajectories 2
Description
To evaluate whether the POSITIVE system improves frailty transitions in pre-frail and frail participants according to FTS-5.
Time Frame
6 months
Title
Physical function 1
Description
To evaluate whether the POSITIVE system improves participants' physical performance according to the Short Physical Performance Battery (SPPB).SPPB scores between 0-12. 0 is the worst and 12 the best value.
Time Frame
6 months
Title
Physical function 2
Description
To evaluate whether the POSITIVE system improves participants' physical performance according to the Gait Speed test (meters/second)
Time Frame
6 months
Title
Basic activities daily living (BADL)
Description
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (basic activities) according to the Barthel Index. Barthel scores between 0-100; 0 is the worst value and 100 the best.
Time Frame
6 months
Title
Disability
Description
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to WHO Disability Assessment Schedule (WHODAS 2.0). Score between 0 to 100 (where 0 = no disability; 100 = full disability)
Time Frame
6 months
Title
Instrumental activities of daily living (IADL)
Description
To evaluate the influence of the POSITIVE system in patients' autonomy every day life (instrumental activities) according to the Lawton and Brody scale. Lawton and Brody scale scores between 0-10; 0 is the worst and 10 the best value.
Time Frame
6 months
Title
Health-related quality of life
Description
To evaluate the influence of the POSITIVE system in the quality of life according to the European Quality of life 5 dimensions-5 levels (EuroQoL 5D-5L). EuroQoL scores between 0-10 and 10 is the worst quality of life.
Time Frame
6 months
Title
Cognitive impairment 1
Description
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the MONTREAL COGNITIVE ASSESSMENT (MoCA test). Scores between 0-30 being 30 the best value.
Time Frame
6 months
Title
Cognitive impairment 2
Description
To evaluate the influence of the POSITIVE system in the cognitive sphere according to the clock drawing test. Score ranges between 0-10. <8 suggests that cognitive impairment (CI)
Time Frame
6 months
Title
Affective sphere
Description
To evaluate the influence of the POSITIVE system in the affective sphere according Geriatric Depression Scale (GDS). Each answer indicating depression (bold 'yes' or 'no) counts one point. Scores greater than 5 are indicative of probable depression. In the experimental site located in Sweden, the version of this scale will be used.
Time Frame
6 months
Title
Caregiver quality of life
Description
To evaluate the influence of the POSITIVE system on the caregiver quality of life according EuroQoL-5D-5L.
Time Frame
6 months
Title
To evaluate the usability of the POSITIVE system according to the System Usability Scale (SUS).
Description
SUS ranges from 0 to 100. A SUS score above a 68 would be considered above average and anything below 68 is below average..
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Age ≥ 70. Living at home. Having a caregiver/relative and/or supervision at home. Barthel ≥ 90. Meet at least 1 criterion from Fried's Criteria. Exclusion criteria: Inadequate home infrastructure to host the required technology. Inability to understand on how to use the POSITIVE system by the participant. Diseases that may affect prescription therapy: History of alcohol/drugs abuse. Living with another participant. Participating in other clinical studies. Three or more hospitalizations in the last year.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Rodrigo Pérez-Rodríguez, PhD
Phone
+34657994364
Email
rprodrigo@salud.madrid.org
First Name & Middle Initial & Last Name or Official Title & Degree
Leocadio Rodríguez-Mañas, MD, PhD
Email
leocadio.rodriguez@salud.madrid.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leocadio Rodríguez-Mañas, MD, PhD
Organizational Affiliation
Hospital Universitario de Getafe
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Rodrigo Pérez-Rodríguez, PhD
Organizational Affiliation
FIB-Hospital Universitario de Getafe
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Lodz
City
Lodz
ZIP/Postal Code
90-419
Country
Poland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tomasz Kostka, PhD
Phone
+48 426793144
Ext
251
Email
tomasz.kostka@umed.lodz.pl
First Name & Middle Initial & Last Name & Degree
Tomasz Kostka, PhD
First Name & Middle Initial & Last Name & Degree
Małgorzata Pigłowska, MsC
Facility Name
Fundación para la Investigación Biomédica - Hospital Universitario de Getafe
City
Getafe
State/Province
Madrid
ZIP/Postal Code
28905
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rodrigo Pérez-Rodríguez, PhD
Phone
+34657994364
Email
rprodrigo@salu.madrid.org
First Name & Middle Initial & Last Name & Degree
Leocadio Rodríguez-Mañas, PdD
First Name & Middle Initial & Last Name & Degree
Rodrigo Pérez-Rodríguez, PhD
Facility Name
Karolinska Institutet
City
Stockholm
ZIP/Postal Code
14183
Country
Sweden
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susanne GE Guidetti, PhD
Phone
+46 (0)739 661636
Email
susanne.guidetti@ki.se
First Name & Middle Initial & Last Name & Degree
Susanne GE Guidetti, MsC
First Name & Middle Initial & Last Name & Degree
Minna Terio, PhD
First Name & Middle Initial & Last Name & Degree
Marina Taloyan, PhD

12. IPD Sharing Statement

Citations:
PubMed Identifier
35999616
Citation
Terio M, Perez-Rodriguez R, Guevara Guevara T, Valdes-Aragones M, Kornevs M, Bjalevik-Chronan S, Taloyan M, Meijer S, Guidetti S. Preventing frailty with the support of a home-monitoring and communication platform among older adults-a study protocol for a randomised-controlled pilot study in Sweden. Pilot Feasibility Stud. 2022 Aug 23;8(1):190. doi: 10.1186/s40814-022-01147-4.
Results Reference
derived
Links:
URL
https://eithealth.eu/project/positive/
Description
Website to the project site within the EIT-Health website (funding body) European Institute of Innovation & technology

Learn more about this trial

Maintaining and imPrOving the intrinSIc capaciTy Involving Primary Care and caregiVErs

We'll reach out to this number within 24 hrs